Abstract
Chromogranin A (CgA), a marker for neuroendocrine cells, is associated with poor prognosis when detected by immunohistochemical technique in prostate tumors.
We have developed an ELISA on microplates for serum CgA and established the normal reference range. We also attempted to find out whether elevated serum CgA levels could be found in patients with various malignant diseases. Because of non‐Gaussian distribution, both medians and 97.5 percentiles of serum CgA levels for men and women of four different age groups were determined. For women, the median and 97.5 percentiles are 20.7 and 63.9 ng/mL for ages 20 to 50, and 32 and 93.8 for 50 to 80 years of age, respectively; for men, they are 27.9 and 78.4 ng/mL for ages 18 to 40 and 41.6 and 92 for 40 to 80 years old, respectively. Elevated serum concentrations of CgA were detectable in patients with prostate cancer not undergoing hormonal treatment, and in patients with various malignant diseases including nonendocrine carcinomas. Most elevated serum CgA levels were associated with sera containing highly elevated serum tumor markers. Drugs targeting neuroendocrine cells should be administered for cancer patients with elevated serum CgA levels. J. Clin. Lab. Anal. 13:312–319, 1999. © 1999 Wiley‐Liss, Inc.
Keywords: neuroendocrine cells, neuroendocrine differentiation, chromogranin A, reference value, malignant diseases
REFERENCES
- 1. Deftos LJ. Chromogranin A. Its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991;12:181–186. Medline [DOI] [PubMed] [Google Scholar]
- 2. Iacangelo AL, Eiden LE. Chromogranin A: Current status as a precursor for bioactive peptides and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept 1995;58:65–88. Medline [DOI] [PubMed] [Google Scholar]
- 3. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide‐producing endocrine neoplasm. N Engl J Med 1986;314:1145–1151. Medline [DOI] [PubMed] [Google Scholar]
- 4. Boomsma F, Bhaggoe UM, Man In‘t Veld AJ, Schalekamp MA. Sensitivity and specificity of a new ELISA method for determination of chromogranin A in the diagnosis of pheochromocytoma and neuroblastoma. Clin Chim Acta 1995;239:57–63. Medline [DOI] [PubMed] [Google Scholar]
- 5. Di SantíAgnese P, Cockett ATK. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357–361. Medline [DOI] [PubMed] [Google Scholar]
- 6. Di SantíAgnese P. Neuroendocrine differentiation in prostatic carcinoma. Cancer 1995;75:1850–1859. [Google Scholar]
- 7. Cussenot O, Villette JM, Valeri A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340–1343. Medline [PubMed] [Google Scholar]
- 8. Van de Voorde WM, Van Poppel HP, Verbeden EK, Oyen RH, Baert OV, Lauweryns JM. Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate. Modern Path 1995;8:591–598.Medline [PubMed] [Google Scholar]
- 9. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF Jr., Cathepsin D. Chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997;80:2109–2119. Medline [PubMed] [Google Scholar]
- 10. Berner A, Nesland J, Waehre H, Glide J, Fossa S. Hormone resistant prostatic adenocarcinoma: An elevation of prognostic factors in pre‐ and post‐treatment specimens. Br J Cancer 1993;68:380–384. Medline [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Wu JT, Astill ME, Liu GH, Stephenson RA. Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients. J Clin Lab Anal 1998;12:205 Medline [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Bajetta E, et al. 5‐Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 1998;15:372–378. [DOI] [PubMed] [Google Scholar]
- 13. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997;30:1–6. Medline [DOI] [PubMed] [Google Scholar]
- 14. Wu JT, Zhang P, Astill ME, Lyons BW, Wu LH. Identification and characterization of c‐erbB‐2 proteins in serum, breast tumor tissue, and SK‐BR‐3 cell line. J Clin Lab Anal 1995;9:141–150. Medline [DOI] [PubMed] [Google Scholar]
- 15. Kadmon D, Thompson TC, Lynch GR. Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol 1991;146:358–361. Medline [DOI] [PubMed] [Google Scholar]
- 16. Bosman FT. Neuroendocrine cells in non‐endocrine tumors: What does it mean? Verh Dtsch Ges Path 1997;81:62–72.Medline [PubMed] [Google Scholar]
- 17. Crawford GA, Gyory AZ, Dallery DM, Kelly D. HPLC of urinary catecholamines in the presence of labetalol, captopril, and α‐methyldopa. Clin Chem 1990;36:1849–1853. Medline [PubMed] [Google Scholar]
- 18. Wu JT. Measurement of AFP and its lectin reactive isoforms in liver diseases and various malignancies. Annals of Clin Lab Sci 1990;20:98–105.Medline [PubMed] [Google Scholar]
- 19. Brown JA, Roberts CS. Elevated serum alpha‐fetoprotein levels in primary gullbladder carcinoma without hepatic involvement. Cancer 1992;70:1838–1843. Medline [DOI] [PubMed] [Google Scholar]
- 20. Hoosein‐NM ; Logothetis‐CJ ; Chung‐LW . Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC‐160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993;149:1209–1213. Medline [DOI] [PubMed] [Google Scholar]
- 21. Mezger MS, O'Connor DT. Plasma chromogranin A in renal failure: Elevation proportional to degree of renal failure, and retention of immunoreactive fragments (abstract). Kidney Int 1986;29:198. [Google Scholar]
- 22. O'Connor DT, Randian MR, Carlton E, Cervenka JH, Hsiao RJ. Rapid radioimmunoassay of circulating chromogranin A: In vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989;35:1631–1637. Medline [PubMed] [Google Scholar]